Assembly Biosciences, Inc., formerly Ventrus Biosciences, Inc., is a biopharmaceutical company. The Company is engaged in discovering treatments for patients with Hepatitis B virus (HBV) and clostridium difficile (CDAD). The Company’s lead program is a clinical cure for HBV. The Company’s second lead program, VEN 310, is based on coating and encapsulation technology that allows for delivery of complex agents to select regions of the gastrointestinal (GI), tract. microbiome therapy in an oral capsule.